Challenging the notion that biotech requires large teams for clinical progress, Coursera Health operates with just nine people. This small team is managing one Phase 1 trial while initiating a second and developing an AI platform. This demonstrates how a focused, highly experienced team can achieve major milestones with extreme capital efficiency.

Since most biotech programs fail (as few as 1 in 10 succeed), a company's survival depends on running a portfolio of multiple programs simultaneously. This requires the discipline to quickly terminate unsuccessful projects and the foresight to have subsequent programs already underway.

To thrive in the volatile biotech industry, employees need more than resilience. They must understand the broader context, from the drug development value chain to the patient's healthcare journey. This systemic view helps them understand the 'why' behind the inevitable strategic pivots, fostering adaptability.

Progress in drug development often hides inside failures. A therapy that fails in one clinical trial can provide critical scientific learnings. One company leveraged insights from a failed study to redesign a subsequent trial, which was successful and led to the drug's approval.

A common failure mode for well-funded biotechs is growing headcount too rapidly. Immunocore's CEO advises new leaders to pace themselves, emphasizing that drug development is a marathon. Prematurely scaling creates fixed expenses that can drain capital before key scientific milestones are hit.

Kainova's CEO describes how navigating multiple financial crises built "scar tissue" within his team. This resilience means they don't get paralyzed by adversity and maintain focus on execution, whether the company has $500 million or $500,000 in the bank. This experience is a key cultural strength.

Unlike most biotechs that start with researchers, CRISPR prioritized hiring manufacturing and process development experts early. This 'backwards' approach was crucial for solving the challenge of scaling cell editing from lab to GMP, which they identified as a primary risk.

Given that 90% of drugs fail in the clinic, the most critical innovation isn't a single brilliant idea. It's building a company with the operational efficiency and financial runway to conduct all ten necessary experiments to find the one that will succeed.

To avoid bureaucratic slowdowns as it scales, Legend Biotech maintains its nimble "startup" culture by constantly focusing the team on patient needs. This patient-centricity, combined with efficient leadership decision-making, ensures the company operates with speed and purpose despite its large size.